Welcome to our dedicated page for GREY MATTERS HEALTH INC, news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on GREY MATTERS HEALTH INC, stock.
Grey Matters Health Inc., formerly Algernon Health Inc. and Algernon Pharmaceuticals Inc., reports healthcare developments tied to its shift toward Alzheimer’s disease diagnostics and dedicated brain PET imaging. News for AGNPF has centered on NovaScan Neuroimaging Clinics, U.S. brain PET scanning center plans, CareMiBrain™ scanner technology, beta-amyloid detection, and clinical uses across dementia and other neurologic conditions.
Company updates also cover capital-structure actions, including name changes and share consolidation, equipment financing, service partnerships, clinic leases, and shareholder or governance matters. The company has also described Algernon NeuroScience’s regulated botanical wellness program involving a proprietary form of DMT and its equity interest in Seyltx, which is advancing Ifenprodil for chronic cough.
Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) reports significant results from a study on ifenprodil for cough suppression. The multi-dose study, conducted by Seyltx, showed a 93% reduction in median cough count in guinea pigs. Seyltx, which acquired Algernon's ifenprodil research program for $2M USD and a 20% equity position, plans to begin patient enrollment for the SILINDA Phase 2b study in early 2025.
Ifenprodil, an NMDA receptor antagonist, achieved near-complete cough suppression at a 30 mg/kg dose. The upcoming SILINDA Phase 2b study will evaluate ifenprodil's efficacy in approximately 240 adults with refractory chronic cough (RCC), with expected treatment arms of 40 mg, 80 mg, and 120 mg TID. Topline data from SILINDA are anticipated by the end of 2026.
Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF), a Canadian clinical-stage pharmaceutical company, has engaged ICP Securities Inc. to provide automated market making services using its proprietary algorithm, ICP Premium™. ICP will be paid CDN $7,500 per month for a three-month initial term, automatically renewing monthly unless canceled with 30 days' notice. ICP will manage supply and demand imbalances of AGNPF shares without third-party funding. Additionally, Algernon has granted 425,000 restricted share units (RSUs) to an employee and a consultant, vesting immediately upon grant and subject to regulatory approval.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.